A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy
Bart J Crielaard1, Steffen van der Wal1, Twan Lammers2, Huong Thu Le1, Wim E Hennink1, Raymond M Schiffelers1, Gert Storm1, Marcel HAM Fens11Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; 2Department of Experimental Molecular...
Guardado en:
Autores principales: | Crielaard BJ, van der Wal S, Lammers T, Le HT, Hennink WE, Schiffelers RM, Storm G, Fens MHAM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/35c8a337cef54e64bf896ec89bc1248a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma
por: Braham MVJ, et al.
Publicado: (2018) -
Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer
por: Sheng Zheng, et al.
Publicado: (2021) -
A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile
por: Srikanth Boinapally, et al.
Publicado: (2021) -
Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
por: Liu T, et al.
Publicado: (2016) -
Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation
por: Ibrahim IM, et al.
Publicado: (2019)